Vanguard Group Inc Cyclacel Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.54 - $21.75 $45,637 - $1.84 Million	-84,514 Reduced 49.29%	86,949 $58,000
Q3 2022 Nov 14, 2022	SELL	$1.23 - $21.9 $191,641 - $3.41 Million	-155,806 Reduced 47.61%	171,463 $250,000
Q4 2021 Feb 14, 2022	SELL	$6.04 - $8.03 $2,349 - $3,123	-389 Reduced 0.12%	327,269 $1.27 Million
Q2 2021 Aug 13, 2021	BUY	$7.59 - $10.48 $2.49 Million - $3.43 Million	327,658 New	327,658 $1.94 Million

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $4.01M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.